STOCK TITAN
  1. Home
  2. News
  3. XOMAP

XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock - $XOMAP STOCK NEWS

Welcome to our dedicated page for XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock news (Ticker: $XOMAP), a resource for investors and traders seeking the latest updates and insights on XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock's position in the market.

News
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
Rhea-AI Summary

XOMA has acquired an economic interest in three women's health assets from Daré Bioscience, Inc., for $22 million upfront. The assets include XACIATO™ (clindamycin phosphate) vaginal gel, Ovaprene®, and Sildenafil Cream. XACIATO™ is FDA-approved for treating bacterial vaginosis, with commercial activities initiated by Organon in 2023. XOMA aims to create additional value for shareholders with these acquisitions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.38%
Tags
none
-
News
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
Rhea-AI Summary
XOMA (NASDAQ: XOMA) has earned a $9 million milestone following the FDA's accelerated approval of Day One Biopharmaceuticals' NDA for OJEMDA™ (tovorafenib), a treatment for pediatric low-grade glioma. XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales. This marks a significant advancement in providing treatment for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
none
-
News
XOMA Corporation Announces Closing of Tender Offer
Rhea-AI Summary
XOMA successfully completed its tender offer to acquire all outstanding shares of Kinnate Biopharma Inc., offering $2.5879 per share in cash plus a contingent value right. The offer included the right to receive 85% of net proceeds from any out license or sale of Kinnate programs within a year of the merger and 100% of net proceeds from the sale of certain assets to Pierre Fabre Laboratories.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
none
News
XOMA Declares Quarterly Preferred Stock Dividends
Rhea-AI Summary
XOMA (Nasdaq: XOMA) announces cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of Series A to receive $0.53906 per share, and Series B holders to receive $0.52344 per depositary share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
dividends
-
News
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
Rhea-AI Summary
XOMA is set to acquire Kinnate Biopharma Inc., adding $9.5 million in cash to its balance sheet and expanding its early-stage programs. The merger agreement includes a cash price per share of $2.5879 for Kinnate stockholders, with the Offer extended until April 2, 2024. The acquisition is subject to certain conditions and is expected to close in April 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
none
-
News
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
Rhea-AI Summary
XOMA Corporation reported strong financial results for Q4 and full year 2023, highlighted by raising $140 million in non-dilutive capital, adding a new commercial asset to their portfolio, and achieving key milestones with partners. The company ended the year with a robust cash position, anticipating significant clinical and regulatory events in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
earnings
News
XOMA to Present at Upcoming Investor Conferences in March
Rhea-AI Summary
XOMA Corporation announces participation in upcoming investor conferences in March 2024, with key executives presenting at TD Cowen Health Care Conference and Leerink Partners Global Biopharma Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
conferences
-
News
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
Rhea-AI Summary
XOMA Corporation announced the acquisition of Kinnate Biopharma Inc. for a base cash price of $2.3352 per share, potentially adding $9.5 million in cash to its balance sheet. The deal includes a contingent value right (CVR) and aims to enhance XOMA's royalty portfolio. The acquisition is expected to close in April 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.28%
Tags
acquisition
-
News
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
Rhea-AI Summary
XOMA Corporation acquires economic interest in DSUVIA® from Talphera, Inc. for $8 million, with a 15% royalty on commercial sales and a significant portion of the 75% royalty from U.S. Department of Defense purchases. XOMA is entitled to no less than 50% of the potential $116.5 million in milestone payments. DSUVIA® received Milestone C approval from the U.S. Department of Defense for use in U.S. Army sets, kits, and outfits (SKOs) and was added to the DoD Joint Deployment Formulary in September 2020. XOMA will receive 100% of all royalties and milestones related to DSUVIA® sales until the Company receives $20 million, after which XOMA fully retains the 15% royalty associated with DSUVIA® commercial sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
acquisition
News
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
Rhea-AI Summary
XOMA Corporation (NASDAQ: XOMA) announced that the FDA has accepted Zevra Therapeutics' New Drug Application for arimoclomol, a first-in-class therapy for Niemann-Pick disease type C (NPC), with a PDUFA target action date of June 21, 2024. XOMA will make a $1 million milestone payment to LadRx based on the FDA's acceptance. The company previously paid LadRx a $5 million upfront payment and acquired a mid-single digit royalty on arimoclomol's commercial sales, with potential milestone payments of up to $52.6 million, net, from Zevra. The transaction also included a royalty rate on commercial sales of aldoxorubicin and potential payments of up to $343 million in development and commercial milestones from ImmunityBio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
clinical trial
Stock XOMAP logo
XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

Nasdaq:XOMAP

XOMAP Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

XOMAP Stock Data

7.95M
4.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
EMERYVILLE

About XOMAP

xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.